share_log

Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $82 Price Target

Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $82 Price Target

Needham重申買入細胞內療法,維持82美元的目標股價
Moomoo 24/7 ·  04/05 05:15

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and maintains $82 price target.

尼德姆分析師阿米·法迪亞重申細胞內療法(納斯達克股票代碼:ITCI)的買入並維持82美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論